Qin Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qin Zheng has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Jing Liu
Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
2 shared publications - Ajit G. Thomas
Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
1 shared publication - Ankit Uniyal
Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
1 shared publication - Barbara S. Slusher
Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
1 shared publication - Chi Zhang
Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
1 shared publication Ilyas Berhane
Johns Hopkins Drug Discovery and Department of Neurology, Johns Hopkins University, Baltimore, MD 21205, USA
1 shared publication
Latest Publications
- 28 July 2026
- Published by Wolters Kluwer Health in Pain
In vivo GCaMP imaging reveals distinct subsets of dorsal root ganglion neurons driving spontaneous pain after nerve injury in mice
Spontaneous pain is a hallmark and debilitating feature of neuropathic pain, yet the mechanisms driving spontaneous pain remain poorly understood. Although abnormal spontaneous activity (SA) in primary sensory neurons has been observed after nerve injury, it remains unclear how such activity is organized across neuronal populations within the dorsal root ganglion (DRG) and how it relates to different pain components. Here, we used large-scale in vivo calcium imaging to examine spontaneous and stimulus-evoked activity in lumbar DRG neurons after spared-nerve injury (SNI). Spared-nerve injury significantly increased the incidence of single-neuron SA in DRG neurons. By combining functional imaging with retrograde labeling, we found that this activity arose not only from injured afferents (51.8%) but also from a substantial population of spared neurons (48.2%) within the same ganglion. Among spared neurons exhibiting spontaneous activity, nearly half (48.4%) showed no detectable responses to a broad panel of mechanical and thermal stimuli under our recording conditions, whereas most responsive neurons retained modality selectivity. Importantly, the incidence of single-neuron SA was positively associated with spontaneous pain-like behavior, but not with mechanical hypersensitivity, after SNI, supporting a direct link between SA of DRG neurons and spontaneous neuropathic pain. Together, these findings show that SA in the DRG is organized across both anatomical and functional dimensions, providing a framework for understanding how abnormal peripheral neuronal activity relates to spontaneous neuropathic pain.
- 28 July 2026
- Published by Wolters Kluwer Health in Pain
In vivo GCaMP imaging reveals distinct subsets of dorsal root ganglion neurons driving spontaneous pain after nerve injury in mice
Spontaneous pain is a hallmark and debilitating feature of neuropathic pain, yet the mechanisms driving spontaneous pain remain poorly understood. Although abnormal spontaneous activity (SA) in primary sensory neurons has been observed after nerve injury, it remains unclear how such activity is organized across neuronal populations within the dorsal root ganglion (DRG) and how it relates to different pain components. Here, we used large-scale in vivo calcium imaging to examine spontaneous and stimulus-evoked activity in lumbar DRG neurons after spared-nerve injury (SNI). Spared-nerve injury significantly increased the incidence of single-neuron SA in DRG neurons. By combining functional imaging with retrograde labeling, we found that this activity arose not only from injured afferents (51.8%) but also from a substantial population of spared neurons (48.2%) within the same ganglion. Among spared neurons exhibiting spontaneous activity, nearly half (48.4%) showed no detectable responses to a broad panel of mechanical and thermal stimuli under our recording conditions, whereas most responsive neurons retained modality selectivity. Importantly, the incidence of single-neuron SA was positively associated with spontaneous pain-like behavior, but not with mechanical hypersensitivity, after SNI, supporting a direct link between SA of DRG neurons and spontaneous neuropathic pain. Together, these findings show that SA in the DRG is organized across both anatomical and functional dimensions, providing a framework for understanding how abnormal peripheral neuronal activity relates to spontaneous neuropathic pain.
- 17 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (829) , eadw9446
An orally bioavailable MrgprX1-positive allosteric modulator alleviates certain neuropathic pain–related behaviors in humanized mice
The human Mas -related G protein–coupled receptor X1 (MrgprX1) represents a promising nonopioid analgesic target because of its selective expression in primary nociceptive sensory neurons. Positive allosteric modulators (PAMs) promote receptor signaling, depending on the availability of endogenous ligands, offering physiological selectivity over orthosteric agonists. We developed an orally bioavailable MrgprX1 PAM, 6-tert-butyl-5-(4-chlorophenyl)-4-(2-fluoro-6-(trifluoromethoxy)phenoxy)thieno[2,3-d]pyrimidine (BCFTP). BCFTP selectively potentiated the functional response of MrgprX1 in HEK293 cells, was metabolically stable, and demonstrated a favorable in vitro safety profile. BCFTP was orally bioavailable and distributed into the spinal cords of wild-type mice. BAM22, an endogenous ligand for MrgprX1, was up-regulated in the spinal cord after nerve injury in both wild-type and humanized MrgprX1 mice and was expressed in peptidergic and nonpeptidergic dorsal root ganglion neurons. Oral administration of BCFTP dose-dependently inhibited heat hyperalgesia and spontaneous pain-like behavior but not mechanical hypersensitivity after sciatic chronic constrictive injury (CCI) in MrgprX1 mice. BCFTP did not have analgesic effects in Mrgpr cluster knockout (Mrgpr −/− ) mice, indicating that the analgesic effects in MrgprX1 mice were MrgprX1 dependent. BCFTP enhanced BAM8-22–induced, MrgprX1-mediated reduction of C-fiber eEPSC amplitudes in spinal lamina II neurons, indicating inhibition of spinal nociceptive synaptic transmission. BCFTP did not induce tolerance or side effects, such as itch, sedation, and motor incoordination, and had no rewarding properties. The mRNAs encoding MrgprX1 and μ-opioid receptors were colocalized in human DRG neurons, and BCFTP synergistically enhanced morphine analgesia in CCI MrgprX1 mice. Our research suggests an approach for developing safer, orally bioavailable MrgprX1 PAM as a nonopioid therapy for neuropathic pain.
- 17 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (829) , eadw9446
An orally bioavailable MrgprX1-positive allosteric modulator alleviates certain neuropathic pain–related behaviors in humanized mice
The human Mas -related G protein–coupled receptor X1 (MrgprX1) represents a promising nonopioid analgesic target because of its selective expression in primary nociceptive sensory neurons. Positive allosteric modulators (PAMs) promote receptor signaling, depending on the availability of endogenous ligands, offering physiological selectivity over orthosteric agonists. We developed an orally bioavailable MrgprX1 PAM, 6-tert-butyl-5-(4-chlorophenyl)-4-(2-fluoro-6-(trifluoromethoxy)phenoxy)thieno[2,3-d]pyrimidine (BCFTP). BCFTP selectively potentiated the functional response of MrgprX1 in HEK293 cells, was metabolically stable, and demonstrated a favorable in vitro safety profile. BCFTP was orally bioavailable and distributed into the spinal cords of wild-type mice. BAM22, an endogenous ligand for MrgprX1, was up-regulated in the spinal cord after nerve injury in both wild-type and humanized MrgprX1 mice and was expressed in peptidergic and nonpeptidergic dorsal root ganglion neurons. Oral administration of BCFTP dose-dependently inhibited heat hyperalgesia and spontaneous pain-like behavior but not mechanical hypersensitivity after sciatic chronic constrictive injury (CCI) in MrgprX1 mice. BCFTP did not have analgesic effects in Mrgpr cluster knockout (Mrgpr −/− ) mice, indicating that the analgesic effects in MrgprX1 mice were MrgprX1 dependent. BCFTP enhanced BAM8-22–induced, MrgprX1-mediated reduction of C-fiber eEPSC amplitudes in spinal lamina II neurons, indicating inhibition of spinal nociceptive synaptic transmission. BCFTP did not induce tolerance or side effects, such as itch, sedation, and motor incoordination, and had no rewarding properties. The mRNAs encoding MrgprX1 and μ-opioid receptors were colocalized in human DRG neurons, and BCFTP synergistically enhanced morphine analgesia in CCI MrgprX1 mice. Our research suggests an approach for developing safer, orally bioavailable MrgprX1 PAM as a nonopioid therapy for neuropathic pain.